SEMA5A-AS1: A Potential Drug Target and Biomarker (G101929338)

Target Name: SEMA5A-AS1

NCBI ID: G101929338

SEMA5A-AS1

Other Name(s): SEMA5A antisense RNA 1 | CTD-2201E9.1

SEMA5A-AS1: A Potential Drug Target and Biomarker

SEMA5A is a gene that encodes a protein involved in the immune response and inflammation. The protein produced by SEMA5A has been shown to play a role in the regulation of dendritic cell maturation and the development of autoimmune diseases. SEMA5A has also been identified as a potential drug target and biomarker for several diseases, including multiple sclerosis and rheumatoid arthritis.

SEMA5A-AS1, a shortened form of SEMA5A, is a RNA molecule that has been shown to have anti-inflammatory effects. SEMA5A-AS1 has been shown to inhibit the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6, in dendritic cells. This suggests that SEMA5A-AS1 may be a useful drug target for diseases that are characterized by chronic inflammation.

SEMA5A has also been shown to play a role in the regulation of immune cell function and development. SEMA5A has been shown to promote the development and maturation of natural killer cells, which are important for immune surveillance of the body. It has also been shown to promote the development of T-cells, which are important for immune surveillance against viruses and other pathogens.

In addition to its role in immune cell function, SEMA5A has also been shown to play a role in the regulation of cell signaling pathways. SEMA5A has been shown to participate in several signaling pathways, including the TGF-beta pathway and the NF-kappa-B pathway. These signaling pathways are involved in the regulation of cell growth, differentiation, and inflammation.

SEMA5A has also been shown to be involved in the development of autoimmune diseases. SEMA5A has been shown to play a role in the regulation of the immune response and the development of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. SEMA5A has been shown to promote the production of autoimmune cytokines, such as TNF-alpha, IL-1, and IL-6, and to regulate the production of anti-autoimmune cytokines, such as IL-10.

In conclusion, SEMA5A-AS1 is a potential drug target and biomarker for several diseases, including multiple sclerosis and rheumatoid arthritis. SEMA5A-AS1 has been shown to have anti-inflammatory and immune-promoting effects, and its role in the regulation of cell signaling pathways and the development of autoimmune diseases makes it an attractive target for drug development. Further research is needed to fully understand the potential mechanisms of SEMA5A-AS1 and its potential as a drug.

Protein Name: SEMA5A Antisense RNA 1

The "SEMA5A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEMA5A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets